Bladder Cancer Therapies Developer Raises $380M in the First …

Jan 25, 2024 · CG reported a cash position of $203.7 million as of the end of the third quarter of 2023. In the IPO filing, the company said it plans to spend about $183.8 million to fund R&D …

CouponFollow Extension

$380
OFF

Bladder Cancer Therapies Developer Raises $380M In The First …

4 weeks from now

Jan 25, 2024 · CG reported a cash position of $203.7 million as of the end of the third quarter of 2023. In the IPO filing, the company said it plans to spend about $183.8 million to fund R&D …

medcitynews.com

$380
OFF

CG Oncology Brings In $380M From First Biotech IPO Of 2023

4 weeks from now

Jan 25, 2024 · Even before that, the $380 million haul puts CG Oncology at the very top end of the IPO scale when judged by 2023 standards. In fact, the only biotech to exceed that level …

fiercebiotech.com

$380
OFF

CG Oncology’s Upsized $380M IPO Is First Biotech To Go

4 weeks from now

Jan 25, 2024 · The bladder cancer-focused biotech’s expected $380 million haul is in gross proceeds before taking out commissions, underwriting discounts and other related expenses. …

biospace.com

$380
OFF

CG Oncology Prices Larger-than-expected $380M IPO In Hopeful …

4 weeks from now

Jan 24, 2024 · Cancer drug developer CG Oncology has raised $380 million in an initial public offering than was ... The offering is the biotechnology sector’s first of 2024 and could be the …

biopharmadive.com

$380
OFF

Bladder Cancer Biotech CG Oncology Raises $380 Million In IPO

4 weeks from now

CG Oncology, a biotech focused on bladder cancer, raised $380 million in its IPO, pricing 20 million shares at $19. Why it matters This is a lustrous green light for the broader IPO market. …

msn.com

$380
OFF

CGON IPO News - Bladder Cancer Biotech CG Oncology Prices …

4 weeks from now

Jan 25, 2024 · CG Oncology, a Phase 3 biotech developing an oncolytic immunotherapy for bladder cancer, raised $380 million by offering 20 million shares at $19, above the range of …

renaissancecapital.com

$380
OFF

CG Oncology Announces Pricing Of Upsized Initial Public Offering

4 weeks from now

Jan 25, 2024 · The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $380.0 million. CG Oncology’s …

yahoo.com

$380
OFF

CG Follows Big IPO With New Results For Bladder Cancer Drug

4 weeks from now

May 3, 2024 · CG Oncology was the first biotech to price an IPO in 2024, bringing in $380 million in proceeds. ... An experimental drug from CG Oncology has driven bladder cancers into …

biopharmadive.com

$100
OFF

With Phase 3 Studies Ongoing In Bladder Cancer, CG Oncology …

4 weeks from now

Jan 7, 2024 · IPO research firm Renaissance Capital estimates the stock offering could raise up to $100 million. CG has applied for a Nasdaq listing under the stock symbol “CGON.” CG has …

medcitynews.com

$200
OFF

Bladder Cancer-focused CG Oncology Files For IPO

4 weeks from now

On 18 January 2024, US-based biotech CG Oncology announced it was looking to raise $200m in an upcoming initial public offering (IPO), which will be the first for the biotech sector in 2024. …

pharmaceutical-technology.com

2%
OFF

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

4 weeks from now

5 days ago · CG Oncology's bladder cancer molecule, cretostimogene, showed high success with a 75.2% complete response rate in a phase 3 monotherapy study. ... Bladder cancer biotech …

stockanalysis.com

$105
OFF

CG Oncology Plans IPO Ahead Of Phase 3 Bladder Cancer Readout

4 weeks from now

Jan 3, 2024 · Five months after reeling in $105 million from a pre-IPO crossover round, CG Oncology is now ready to take the plunge and go public. | Five months after reeling in $105 …

fiercebiotech.com

$1
OFF

Dublin-listed Malin’s Shot In The Arm From Share In $1.5bn Deal Will ...

4 weeks from now

1 day ago · Malin, now led by executive director Fiona Dunlevy and executive chairman Liam Daniel, sold its stake in CG Oncology, which has a bladder cancer treatment in late clinical …

irishtimes.com

$105
OFF

CG Raises $105M Crossover Round To Fund Phase 3 Cancer Trial

4 weeks from now

Aug 2, 2023 · CG Oncology has raised the rarely seen crossover round. Once ubiquitous, the pre-IPO rounds have dried up in the biotech bear market—but CG’s fully enrolled phase 3 bladder …

fiercebiotech.com

FAQs about Bladder Cancer Therapies Developer Raises $380M in the First … Coupon?

Will CG oncology be the first biotech IPO?

CG is now in the running to be among the first biotech IPOs of the new year, against a backdrop of mixed predictions on whether public listings will recover from their two-year slump. Five months after reeling in $105 million from a pre-IPO crossover round, CG Oncology is now ready to take the plunge and go public. ...

When will CG oncology start a bladder cancer study?

The company said in the filing that it expects to begin this study in the second half of 2024. CG Oncology’s main asset is cretostimogene, an oncolytic virus in late-stage development as a treatment for advanced bladder cancer. The IPO filing follows the report of interim efficacy data showing a 75% complete response rate. ...

Will CG oncology raise $100 million in a public offering?

IRVINE, Calif.-- (BUSINESS WIRE)--CG Oncology Announces Pricing of Upsized Initial Public Offering. CG Oncology, a Phase 3 biotech developing an oncolytic immunotherapy for bladder cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. ...

Why did CG Oncology IPO?

The IPO filing follows the report of interim efficacy data showing a 75% complete response rate. When bladder cancer does not respond to the current standard of care therapy, the next treatment option is surgery to completely remove the bladder. CG Oncology aims to give patients another choice. ...

Will CG IPO a biotech company in 2024?

The offering is the biotechnology sector’s first of 2024 and could be the start of an early IPO run. CG is one of five biotech companies to reveal IPO plans since January. One other, ArriVent Biopharma, is expected to price an offering this week. Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. ...

Can CG oncology cure bladder cancer?

When bladder cancer does not respond to the current standard of care therapy, the next treatment option is surgery to completely remove the bladder. CG Oncology aims to give patients another choice. The biotech has reached late-stage development with an oncolytic virus and it’s now looking to the public markets to finance clinical testing. ...